ImmunityBio's Anktiva launch is driving explosive top-line growth, with revenue surging 668% year-over-year to $51.2M in 2026Q2, marking the eighth consecutive quarter of sequential growth. However, the company remains deeply unprofitable, with operating losse...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth is accelerating, with 2026Q2 revenue of $51.2M up 668% year-over-year, but operating losses widened to -$61.7M as R&D and SG&A expenses of $108.3M outpace gross profit, reflecting a lack of operating leverage.
ImmunityBio is focused on developing next-generation therapies to conquer cancer by leveraging the body's immune system.
The company is transitioning into a commercial-stage biotech firm, which could drive revenue growth and market validation.
Multiple bullish theses highlight investor confidence in ImmunityBio's potential, as seen in various investment forums and articles.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$0.22-175.0% vs -$0.08 | $51M+3.1% vs $50M |
Q2 2026 May 7, 2026 | -$0.62-675.0% vs -$0.08 | $44M+2.6% vs $43M |
Q1 2026 Feb 23, 2026 | -$0.06+25.0% vs -$0.08 | $38M-0.2% vs $38M |
Q4 2025 Nov 4, 2025 | -$0.07+30.0% vs -$0.10 | $32M-15.1% vs $38M |
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tidal Investments LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 252,048 shares of the company's stock, valued at approximately $2,207,000. Several other hedge funds and other institutional investors have also
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year target
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
Benchmark IBRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ImmunityBio, Inc. (IBRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.63 | $9.04B | -22.71 | 668.31% | -310.18% | — | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — | |
| $2.43 | $283.24M | -2.11 | -51.24% | -1941.09% | -65.08% | — | |
| $0.95 | $1.86M | -0.08 | -13.43% | -490.33% | -1035.26% | — | |
| $1.31 | $166.62M | -1.17 | 14.85% | -123.03% | — | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
ImmunityBio, Inc. (IBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ImmunityBio, Inc. (IBRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jul 30, 2026·SEC
Jun 10, 2026·SEC
Get notified when IBRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ImmunityBio, Inc. (IBRX) stock FAQ — growth, dividends, profitability & financials explained
ImmunityBio, Inc. (IBRX) reported $165.8M in revenue for fiscal year 2025. This represents a 27532% increase from $0.6M in 2013.
ImmunityBio, Inc. (IBRX) grew revenue by 668.3% over the past year. This is strong growth.
ImmunityBio, Inc. (IBRX) reported a net loss of $992.4M for fiscal year 2025.
ImmunityBio, Inc. (IBRX) had negative free cash flow of $365.6M in fiscal year 2025, likely due to heavy capital investments.
